Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Successfully completed live trading test, Bank of Korea participates in BIS global tokenization payment project

Successfully completed live trading test, Bank of Korea participates in BIS global tokenization payment project

Odaily星球日报Odaily星球日报2026/07/30 09:31
Show original
According to Odaily, the Bank of Korea has participated in the real transaction testing of the global payment and settlement project Agora, led by the Bank for International Settlements, and has successfully completed transactions using tokenized reserve funds. A total of 28 institutions took part in this test, including the Bank of Korea, central banks from various countries, and private financial institutions. The currencies involved included the Korean won, US dollar, euro, pound sterling, Swiss franc, and Japanese yen. Domestic Korean institutions that participated included KB Kookmin Bank, NongHyup Bank, Shinhan Bank, Woori Bank, and Hana Bank. The participating institutions conducted real transaction testing valued at approximately 800,000 Swiss francs, covering multiple currencies with a total of 17 transaction scenarios tested. The Bank of Korea stated that in the future, the Agora project plans to conduct more real transaction tests by identifying transaction types and scenarios not covered in this round of testing.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12